ARTICLE | Company News

Threshold, Merck KGaA deal

February 6, 2012 8:00 AM UTC

The companies partnered to co-develop and commercialize Threshold's cancer product TH-302. The product, a hypoxia-activated cytotoxic 2-nitroimidazole prodrug of the DNA alkylator bromoisophosphoramide mustard (Br-IPM), is in Phase III testing to treat soft tissue sarcoma (STS) as well as a Phase II trial for advanced pancreatic cancer for which data are expected this month. ...